Emma Guttman-Yassky, MD, PhD - Taking a New Approach to Relieving Atopic Dermatitis: The Evidence for OX40/OX40L Therapies

CME in Minutes: Education in Dermatology
29/05/2025 15 min

Listen "Emma Guttman-Yassky, MD, PhD - Taking a New Approach to Relieving Atopic Dermatitis: The Evidence for OX40/OX40L Therapies"

Descargar episodio Ver en sitio original

Episode Synopsis

Please visit answersincme.com/CKC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evolving role of OX40/OX40L-targeted monoclonal antibodies (mAbs) for the treatment of moderate to severe atopic dermatitis.Upon completion of this activity, participants should be better able to: Recognize the rationale for targeting OX40/OX40L in the treatment of moderate to severe atopic dermatitis (AD); Review the clinical profiles of OX40/OX40L-targeted monoclonal antibodies in treating moderate to severe AD; and Outline clinical considerations for the future integration of OX40/OX40L-targeted mAbs into treatment plans for moderate to severe AD.

More episodes of the podcast CME in Minutes: Education in Dermatology

Linda Stein Gold, MD / April W. Armstrong, MD, MPH / Erin Boh, MD, PhD - Personalizing Psoriasis Care Across the Map: Navigating Regional Barriers to Integrating Oral Small Molecule Treatment for Moderate to Severe Disease 07/11/2025
Nikhil I. Khushalani, MD - From Trial to Team: Optimizing Adjuvant Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma 22/09/2025
April W. Armstrong, MD, MPH / Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - Next-Generation Treatments for Moderate-to-Severe Plaque Psoriasis: What's New in TYK2 04/08/2025
Neil D. Gross, MD, FACS - Evolving the Multi-Modal Approach for Resectable Cutaneous Squamous Cell Carcinoma: A Multidisciplinary Assessment of Current and Emerging Immunotherapeutic Strategies 11/07/2025
Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations 07/07/2025
Nathan Falk, MD, MBA, FAAFP - Making Sense of Type 2 Inflammation Crosstalk in Chronic Diseases: Perspectives on Improving Emergency and Primary Care Collaboration 02/04/2025
Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers 17/12/2024
Erin Barrett (Wei), MD - Focusing on the Patient to Enhance Therapeutic Care: Advancing Early Diagnosis and Management of Bullous Pemphigoid 29/11/2024
Nikhil I. Khushalani, MD - Practical Guidance for Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: Using Immunotherapy Effectively in Clinical Practice 06/11/2024
Vishal A. Patel, MD - Selecting and Sequencing Systemic Treatment for Advanced Basal Cell Carcinoma 28/10/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA